|
|
|
| Efficacy of Evolocumab Combined with Rosuvastatin in Patients with Cerebral Infarction Complicated with Intracranial and Extracranial Arterial Stenosis |
| DONG Peng, LIU Jieyi, LIU Ye, WU Minlu |
| Department of Neurology, the 905th Hospital of Chinese People's Liberation Army Navy, Shanghai 200000 |
|
|
|
|
Abstract 【Objective】To analyze the clinical efficacy of combined application of evolocumab and rosuvastatin for patients suffering from cerebral infarction accompanied by intracranial and extracranial arterial stenosis. 【Methods】A total of 88 patients with cerebral infarction and intracranial and extracranial arterial stenosis treated from June 2023 to June 2025 were enrolled. Patients were divided into the control group and the observation group, with 44 cases in each group, according to treatment regimens. The control group received rosuvastatin monotherapy alone, while the observation group adopted the combined therapy of evolocumab and rosuvastatin. Clinical efficacy, blood lipid levels before and after treatment, relief time of clinical symptoms and incidence of adverse reactions were compared between two groups. 【Results】The observation group obtained higher overall clinical effective rate than the control group (all P<0.05). After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) decreased, and high-density lipoprotein cholesterol (HDL-C) increased in the observation group compared to the control group, with significant differences(all P<0.05). The observation group showed obviously shorter relief time of various clinical symptoms (all P<0.05). No significant difference existed in the total incidence of adverse reactions between two groups (P>0.05). 【Conclusion】Combined treatment with both evolocumab and rosuvastatin improves therapeutic effect obviously, optimizes blood lipid metabolism effectively and shortens symptom relief time safely in patients with cerebral infarction complicate with intracranial and extracranial arterial stenosis.
|
|
Received: 07 January 2026
|
|
|
|
|
|
[1] 路凯,马宇,马龙,等. CTA联合CTP评估头穴透刺对脑梗死伴大脑中动脉狭窄患者侧支循环及脑血管储备能力影响[J].辽宁中医药大学学报,2025,27(9):184-189.
[2] 刘翠芳,郑迎迎,刘红旗. CT灌注与磁共振灌注成像对大脑中动脉狭窄脑梗死老年患者大剂量他汀治疗效果评价的比较研究[J].老年医学与保健,2025,31(4):1080-1083.
[3] 张辉,王利. 依洛尤单抗在超高危动脉粥样硬化性心血管疾病患者中的疗效观察[J].实用药物与临床,2023,26(5):417-421.
[4] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
[5] 胡燕,苗燕,陈津津,等. 急性大脑中动脉狭窄脑梗死磁共振检查T2-FLAIR高信号血管征对患者神经功能及预后的影响[J].陕西医学杂志,2025,54(7):939-943.
[6] Wang Y, Li H L, Xu X H, et al. New asymptomatic thrombosis caused by carotid web during the acute period of cerebral infarction[J].BMC Neurol,2023, 23(1): 264.
[7] 何世栋. 氯吡格雷联合阿托伐他汀治疗老年急性脑梗死伴颅内动脉狭窄的疗效及其对血脂、血液流变学、c反应蛋白的影响研究[J].贵州医药,2023,47(2):239-241.
[8] 陈熊高,杨光伟,刘志平,等. 刺五加注射液联合尤瑞克林治疗急性脑梗死的临床研究[J].现代药物与临床,2025,40(6):1406-1410.
[9] 钟凯,毛炜,周强. CT灌注成像参数与血清CTRP-3、LDL-C及MMP-9对急性脑梗死后出血转化的评价[J].中国医学装备,2023,20(12):62-66.
[10] 吴洁琼,李红月,王佳星,等. 血脂康胶囊联合阿利西尤单抗对他汀类药物不耐受动脉粥样硬化性心血管疾病患者动脉硬化程度和血脂水平的影响[J].中国医药,2025,20(5):662-667.
[11] 陈伟明,朱志栋,王逸明,等. 英克司兰与依洛尤单抗联合他汀类药物对超高危动脉粥样硬化性心血管病患者的降脂疗效比较[J].中国临床药学杂志,2025,34(1):45-50.
[12] 柏永春,张召丰,李洁. 阿托伐他汀与阿司匹林用于脑梗死后偏瘫患者的疗效[J].中国药物应用与监测,2025,22(9):1497-1501.
[13] Li P X, Tan J, Zhang C, et al. Clinical outcomes and safety profile of early low-density lipoprotein cholesterol target attainment in patients with atherosclerotic cerebral infarction: a prospective cohort study[J].Nutr Metab Cardiovas,2026: 104768.
[14] 周晓亚,陈国芳,张文丽,等. 前蛋白转化酶枯草溶菌素9抑制剂联合瑞舒伐他汀对急性缺血性脑卒中患者血脂水平和短期预后的影响[J].中华神经科杂志,2024,57(6):625-633. |
|
|
|
2026, Vol. 43 
